FDA Grants Priority Review for Supplemental NDA for a Cardiovascular Risk Reduction Indication for Amarin's Vascepa

 

May 29, 2019—Amarin Corporation plc announced that its supplemental new drug application (sNDA) for Vascepav (icosapent ethyl) capsules has been accepted for filing and granted Priority Review designation by the FDA. The FDA assigned a Prescription Drug User Fee Act goal date for the sNDA of September 28, 2019, which is approximately 4 months earlier under Priority Review than the anticipated standard 10-month review for applications.

If approved, Vascepa will be indicated to reduce residual cardiovascular risk in patients with statin-managed low-density lipoprotein cholesterol (LDL-C), but persistently elevated triglycerides. Vascepa is currently indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG > 500 mg/dL) hypertriglyceridemia.

According to the company, the sNDA for Vascepa is based on the landmark REDUCE-IT cardiovascular outcomes study.

Deepak L. Bhatt, MD, who is Global Principal Investigator and Steering Committee Chair for REDUCE-IT, presented the study's primary results at the American Heart Association's 2018 Scientific Sessions held November 10–12 in Chicago, Illinois. The results were simultaneously published online by Dr. Bhatt, MD, et al in The New England Journal of Medicine (2019;380:11–22). In March, additional results and analysis of total recurrent events observed were published by Fabien Picard, MD, et al in Journal of American College of Cardiology (2019;73:1362-1364).

The company advised that in REDUCE-IT, Vascepa achieved the primary endpoint with a 25% relative risk reduction compared with placebo (95% confidence interval [CI], 0.68–0.83; P < .001) in the first occurrence of a major adverse cardiovascular event (MACE; a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina requiring hospitalization) in the intent-to-treat population. Additionally, Vascepa achieved the study’s key secondary endpoint with a 26% relative risk reduction (hazard ratio, 0.74; 95% CI, 0.65–0.83; P < .001) in three-point MACE in the intent-to-treat population consisting of a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, noted Amarin.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.